To provide an overview of influenza surveillance efforts in the US.
Approach:
Key Findings:
Influenza activity peaked in late December 2025, with A(H3N2) predominating.
Hospitalization rates were among the highest in the last 15 years, primarily due to A(H3N2) infections.
Vaccine effectiveness was estimated at 47% in children and 26% in adults against hospitalizations.
Interpretation:
The 2025-2026 influenza season was characterized by significant epidemiological changes, with high hospitalization rates and notable vaccine effectiveness challenges.
Limitations:
Data may not fully represent all geographic areas due to varying participation in surveillance networks.
Potential biases in hospitalization reporting and vaccine effectiveness estimates.
Conclusion:
The ongoing evolution of influenza epidemiology necessitates robust surveillance systems to adapt to emerging trends and challenges.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.